P-127. Timing and Use of Adjunctive Steroids in Adults with Bacterial Meningitis in the United States

P-127. 美国成人细菌性脑膜炎辅助性类固醇治疗的时机和使用情况

阅读:2

Abstract

BACKGROUND: Adjunctive steroids decrease mortality in adults with bacterial meningitis. Steroids given within 20 minutes, 4 hours and 12 hours after the first dose of antibiotics are advocated by the Infectious Diseases Society of America (IDSA), European, and United Kingdom (UK) guidelines, respectively. Compliance with these guidelines in the United States (US) is unknown. [Figure: see text] METHODS: Retrospective observational study of 230 adults with community-acquired bacterial meningitis at 16 hospitals in Houston, Texas from December 2004-January 2023. RESULTS: Among the 230 patients with bacterial meningitis, a total of 171/230 (74%) got adjunctive steroids. Steroids were more likely used in patients with comorbidities, those with pneumococcal etiology, positive Gram stain, a higher CSF protein and with lower CSF glucose (P< 0.05). There was no association between the use of steroids and history of immunosuppression, fever, headache, stiff neck, Glasgow coma scale, seizures, focal neurological exam or serum WBC counts (P >0.05). Out of the 171 patients who were given steroids, 37 (22%) received steroids within 20 mins, 83 (48%) within 4 hours, and 125 (73%) within 12 hours per IDSA, European, and UK guidelines, respectively. Use of steroids in this study by any timeline was not associated with improved clinical outcomes. CONCLUSION: Timing and use of adjunctive steroids in adults with bacterial meningitis remain suboptimal in the US and could account for the lack of impact on clinical outcome. DISCLOSURES: Rodrigo Hasbun, MD MPH FIDSA, Biomeriaux: Grant/Research Support|Biomeriaux: research funding and personal fees to help with Monte Carlo simulation studies evaluating impact of cost on adults and children

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。